Rethinking ME/CFS Diagnostic Reference Intervals via Machine Learning, and the Utility of Activin B for Defining Symptom Severity
- Supplementary File 1:
PDF-Document (PDF, 153 KiB)
Lidbury, B.A.; Kita, B.; Richardson, A.M.; Lewis, D.P.; Privitera, E.; Hayward, S.; de Kretser, D.; Hedger, M. Rethinking ME/CFS Diagnostic Reference Intervals via Machine Learning, and the Utility of Activin B for Defining Symptom Severity. Diagnostics 2019, 9, 79. https://doi.org/10.3390/diagnostics9030079
Lidbury BA, Kita B, Richardson AM, Lewis DP, Privitera E, Hayward S, de Kretser D, Hedger M. Rethinking ME/CFS Diagnostic Reference Intervals via Machine Learning, and the Utility of Activin B for Defining Symptom Severity. Diagnostics. 2019; 9(3):79. https://doi.org/10.3390/diagnostics9030079
Chicago/Turabian StyleLidbury, Brett A., Badia Kita, Alice M. Richardson, Donald P. Lewis, Edwina Privitera, Susan Hayward, David de Kretser, and Mark Hedger. 2019. "Rethinking ME/CFS Diagnostic Reference Intervals via Machine Learning, and the Utility of Activin B for Defining Symptom Severity" Diagnostics 9, no. 3: 79. https://doi.org/10.3390/diagnostics9030079


